Pamidronate Treatment of Osteonecrosis of the Hip in Young Male

A. Lo Gullo, R. Talotta, M. Atteritano*
Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy

© 2018 Lo Gullo et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address for correspondence to this auther at the Department of Clinical and Experimental Medicine, University of Messina, Pad. C, 4th floor, A.O.U. Policlinico “G. Martino” Via C. Valeria, 98124 Messina, Italy; Tel: +39 090 2212388; Fax: +39 090 2935162; E-mail:



Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability.


Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease, delaying the time of bone collapsing.


A 27-years-old male was treated with pamidronate for three consecutive days every four weeks.


After three months the patient came back at control showing a marked improvement in clinical condition, referred full recover from pain and dysmotility with improvement of the quality of life, which was confirmed by the result of MRI he had for control.


We reported a case of aseptic osteonecrosis of the hip which was successfully treated pamidronate at dosage of 45 mg.

Keywords: Aseptic osteonecrosis, CRP, MRI, Pamidronate, Hip, Dysmotility.